<DOC>
	<DOCNO>NCT01567670</DOCNO>
	<brief_summary>The investigator study new treatment one subtype obesity . Obesity disease . It symptom several different disease . These disease distinct etiology , cause aberration different mechanism . Forms obesity cause non-critical mechanism might correct fairly easily safely . The investigator interested overeat obesity cause opioidergic system . The opioidergic system appear responsible subtype obesity associate binge eat disorder ( BED ) . People , especially right genetic predisposition , become addict food release endorphin , way people become addicted exogenous opiate drug release endorphins . The particular application propose clinical trial intranasal ( IN ) naloxone . The peak level naloxone similar bioavailability naloxone intranasally 100 % ( ) available IV . '' IN administration naloxone since broadly test human , well , show safe , pharmacokinetics similar naloxone give injection .</brief_summary>
	<brief_title>Clinical Trial Binge Eating Disorder , Treatment With Naloxone Spray</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Feeding Eating Disorders</mesh_term>
	<mesh_term>Binge-Eating Disorder</mesh_term>
	<mesh_term>Bulimia</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<criteria>Binge eat disorder ( DSMIV ) body mass index ( BMI ) &gt; 25 Binge eat screen &gt; 20 Pregnancy Drug usage Retarded Severe mental illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>